OJJAARA (MOMELOTINIB )
Price
FAQ's
Details
Patients Stories
Important Guide
Momelotinib is an oral JAK1/JAK2 and ACVR1 inhibitor indicated for the treatment of myelofibrosis with anemia. It helps reduce spleen enlargement, improve disease-related symptoms, and address anemia, making it a valuable treatment option for patients with intermediate- or high-risk myelofibrosis.

